Hero MotoCorp, the country’s largest two-wheeler manufacturer, posted a modest set of numbers for the March quarter (Q4FY25), with earnings slightly ahead of Street expectations. Consolidated net profit rose 6.4% year-on-year to ₹1,081 crore, compared to ₹1,016 crore projected by analysts in a CNBC-TV18 poll. In the same quarter last year, profit stood at ₹1,061 crore.
Revenue from operations during the quarter came in at ₹9,939 crore, registering a 4.4% year-on-year growth over ₹9,519 crore in Q4FY24. The figure also exceeded the Street estimate of ₹9,705 crore, aided by a price hike and a better product mix.
Earnings before interest, tax, depreciation and amortisation (EBITDA) rose 4.4% YoY to ₹1,417.7 crore from ₹1,359 crore a year earlier, also slightly higher than the CNBC-TV18 poll estimate of ₹1,362 crore. EBITDA margin for the quarter stood at 14.26%, almost flat compared to 14.30% in the same period last year. Margins remained steady thanks to continued cost optimisation efforts, stable commodity prices, and improved efficiencies.
The company’s board has recommended a final dividend of ₹65 per equity share (face value ₹2), subject to shareholder approval at its upcoming 42nd Annual General Meeting (AGM). The record date has been set as July 24, 2025, and payment will be made within 30 days of declaration at the AGM.
Hero MotoCorp also reported its highest-ever full-year revenue and net profit in FY25, with annual revenue from operations touching ₹40,756 crore and profit after tax at ₹4,610 crore.
Commenting on the performance, Executive Director and Acting CEO Vikram S Kasbekar said the company has reinforced its leadership position for the 24th consecutive year, supported by growth in the core commuter segment and strong traction in the 125cc category. He also said that the upcoming electric vehicle (EV) launch is expected to bolster momentum heading into FY26.
Shares of Hero MotoCorp climbed 2% and are trading at Rs. 4064.30 per share following the earnings release.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.